Filtered By:
Condition: Heart Failure
Education: Study
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 189 results found since Jan 2013.

Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?
Abstract Plasma catecholamines may play an important role in Takotsubo cardiomyopathy (TCM) pathophysiology. Patients with disproportionately high catecholamine responses to stressful events are prone to worse clinical outcomes. Catecholamines stimulate platelet activation and, therefore, may determine the clinical presentation and outcomes of TCM. We conducted a retrospective, descriptive study TCM patients admitted between 2003 and 2013 to Einstein Medical Center, Philadelphia, PA, USA and Danbury Hospital, Danbury, CT, USA. A total of 206 patients met Modified Mayo TCM criteria. Using a multiple logistic model,...
Source: Heart and Vessels - August 13, 2015 Category: Cardiology Source Type: research

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
Conclusions The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.gov NCT00468923).
Source: Canadian Journal of Cardiology - February 25, 2016 Category: Cardiology Source Type: research

Better than Aspirin for Your Heart
If you’ve been diagnosed with heart disease, the chances are you’ve been told to take low-dose aspirin every day as a preventative measure against heart attack and stroke. It’s most commonly prescribed for patients with congestive heart failure. This is the inability of your heart to pump as much blood as your body needs. And this is a big worry to me, because there is very little evidence that aspirin helps. In fact, regular use of aspirin — even baby aspirin — can do you more harm than good. Common Aspirin Beliefs The idea is that aspirin thins the blood, making it easier to pump.  It is also s...
Source: Al Sears, MD Natural Remedies - April 1, 2016 Category: Complementary Medicine Authors: Al Sears Tags: Heart Health Source Type: news

Impact of Chronic Nitrate Therapy in Patients With Ischemic Heart Failure
Conclusion: Long-term nitrates use in patients with ischemic HF was associated with higher occurrence of ischemic events, defined as fatal or nonfatal myocardial infarction or stroke. Our results, although from a retrospective analysis, do not support a role for chronic nitrate use in HF.
Source: Journal of Cardiovascular Pharmacology and Therapeutics - August 4, 2016 Category: Cardiology Authors: Moreira-Silva, S., Urbano, J., Nogueira-Silva, L., Bettencourt, P., Pimenta, J. Tags: Clinical Study Source Type: research

Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study.
CONCLUSION: Patients with GCA present a high risk of cardiovascular hospitalization after diagnosis. In patients with incident GCA from the Midi-Pyrenees region, southern France, statin therapy was associated with reduced cardiovascular hospitalizations. PMID: 27585686 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - September 3, 2016 Category: Rheumatology Tags: J Rheumatol Source Type: research

ApoA-1 Mimetic Peptides Promoting Lipid Efflux from Cells for Treatment of Vascular Disorders
This invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coronary syndrome, angina pectoris, ...
Source: NIH OTT Licensing Opportunities - February 1, 2008 Category: Research Authors: ajoyprabhu3 Source Type: research

A Multimodality Strategy for Cardiovascular Risk Assessment: Performance in Two Population-Based Cohorts.
Conclusions -Among adults without known CVD, a novel multimodality testing strategy using ECG-LVH, CAC, NT-proBNP, hs-cTnT and hs-CRP significantly improved global CVD and ASCVD risk assessment. PMID: 28360032 [PubMed - as supplied by publisher]
Source: Circulation - March 30, 2017 Category: Cardiology Authors: de Lemos JA, Ayers CR, Levine BD, deFilippi CR, Wang TJ, Hundley WG, Berry JD, Seliger SL, McGuire DK, Ouyang P, Drazner MH, Budoff MJ, Greenland P, Ballantyne CM, Khera A Tags: Circulation Source Type: research

Beta-blockers 'useless' for many heart attack patients, study reports
Conclusion This study aimed to see whether beta blockers reduce mortality in people who've had a heart attack but who don't have heart failure or systolic dysfunction. It found no difference between those who were and those who were not given beta-blockers on discharge from hospital. The authors say this adds to the evidence that routine prescription of beta blockers might not be needed for patients without heart failure following a heart attack. Current UK guidelines recommend all people who have had a heart attack take beta blockers for at least one year to reduce risk of recurrent events. Only people with heart failure ...
Source: NHS News Feed - May 30, 2017 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Incident Cardiovascular Disease Among Adults with Blood Pressure < 140/90 mm Hg.
Conclusions -While higher BP levels are associated with increased CVD risk, in the modern era, the majority of incident CVD events occur in US adults with SBP/DBP<140/90 mmHg. Although absolute risk and cost-effectiveness should be considered, additional CVD risk reduction measures for adults with SBP/DBP<140/90 mmHg at high risk for CVD may be warranted. PMID: 28634217 [PubMed - as supplied by publisher]
Source: Circulation - June 20, 2017 Category: Cardiology Authors: Tajeu GS, Booth JN, Colantonio LD, Gottesman RF, Howard G, Lackland DT, O'Brien E, Oparil S, Ravenell JE, Safford MM, Seals SR, Shimbo D, Shea S, Spruill TM, Tanner RM, Muntner P Tags: Circulation Source Type: research

Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation.
CONCLUSIONS: Adherence to therapy with statins reduced the risk of both death and cardiovascular morbidity in patients aged 80years or older. PMID: 28958460 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - September 25, 2017 Category: Internal Medicine Authors: Corrao G, Monzio Compagnoni M, Franchi M, Cantarutti A, Pugni P, Merlino L, Catapano AL, Mancia G Tags: Eur J Intern Med Source Type: research

Mechanisms, Clinical Significance and Prevention of Cognitive Impairment in Atrial Fibrillation
Publication date: Available online 6 October 2017 Source:Canadian Journal of Cardiology Author(s): Lena Rivard, Paul Khairy Atrial fibrillation (AF) and dementia are major health issues, with growing evidence suggesting a consistent association between AF and all forms of dementia. Although dementia and AF share several risk factors, the association appears to be independent of a history of clinical stroke and other comorbidities such as hypertension, heart failure, and diabetes. Proposed mechanisms linking AF to cognitive decline include altered hemodynamics resulting in cerebral hypoperfusion, inflammation, genetic fact...
Source: Canadian Journal of Cardiology - October 7, 2017 Category: Cardiology Source Type: research

Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 3, 2018 Category: Drugs & Pharmacology Authors: Doumas M, Imprialos Κ, Stavropoulos K, Reklou A, Sachinidis A, Athyros VG Tags: Curr Pharm Des Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Weight-Loss Surgery Dramatically Lowers the Risk of Early Death, a New Study Finds
For decades, doctors have known that losing weight can significantly lower risk of heart disease and by extension, reduce the risk of dying from heart-related events such as stroke and heart attack. Studies have shown that both lifestyle changes including diet and exercise as well as medications and weight-loss surgery can improve heart disease risk factors such as obesity and diabetes, for example, but data supporting the benefits of any of these approaches in actually lowering rates of heart events such as heart attack and atrial fibrillation, or in reducing early deaths from heart disease, have been less robust. The dat...
Source: TIME: Health - September 2, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized diabetes Heart Disease Source Type: news

Study: Fish Oil Doesn ’ t Seem To Prevent Heart Problems
This study is consistent with earlier trials. The US Food and Drug Administration approved the fish oil-based drug Vascepa for heart attack and stroke prevention in 2019. Nissen hopes the FDA will take a look at these studies and reconsider that decision. “But it’s hard to get something undone once the genie gets out of the bottle,” he said. An editorial in the journal that accompanies the study written by Dr. Gregory Curfman, assistant professor of medicine at Harvard Medical School, also suggested the FDA should require a postmarketing clinical trial of a high-dose of fish oil, such as Vascepa, vs. corn...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 16, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Health Syndicated CBSN Boston CNN fish oil Source Type: news